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Some patients with group 3 pulmonary hypertension (PH) (PH due to lung disease and/or hypoxia) exhibit
disproportionately advanced or “out-of-proportion” PH. In the present case series, we document four
consecutive patients with progressive out-of-proportion group 3 PH. All patients exhibited progressive dys-
pneaor peripheral edemaandwere treatedbypulmonaryartery hypertension (PAH)-speciﬁc vasodilator(s).At
the follow-up assessment 3e4 months later, symptoms/signs and pulmonary hemodynamic measurements
improved in all four patients (45  8% decrease in pulmonary vascular resistance). Pulmonary oxygenation
deteriorated in one patient but improved or did not signiﬁcantly change in the remaining three cases.
Importantly, the background lung parenchymal disease (early-onset chronic obstructive pulmonary disease,
rheumatoid arthritis-associated interstitial pneumonia, and combined pulmonary ﬁbrosis and emphysema)
was stable uponprogression of the right heart failure symptoms/signs, and also during the 3e4-month follow-
upperiod inall cases.Wehereindescribe the clinical featuresof the fourcases anddiscuss thepotential beneﬁts
and risks of PAH-speciﬁc treatment in this emerging population.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction In the present case report series, we document four consecutivePulmonary hypertension (PH) is deﬁned as mean pulmonary
arterial pressure (MPAP) 25 mmHg at rest. PH is classiﬁed as
group 3 when it develops as a result of lung disease and/or hyp-
oxia.1 Oxygen supplementation is the treatment of choice for this
population,1 whereas the use of pulmonary arterial hypertension
(PAH)-speciﬁc vasodilators is not recommended because of the lack
of evidence and possible deterioration of ventilation/perfusion
mismatch and hypoxia.2,3
The degree of PH is modest in most group 3 PH cases.4,5 However,
recent studies have highlighted a subset of patients who exhibit
disproportionately advanced or “out-of-proportion” PH.6e8 This PH is
clinically characterized by dyspnea insufﬁciently explained by lung
mechanical disturbances1 and, more recently, a German consensus
group has proposed new criteria for this population.7 It can be
assumed that patients with Group 3 out-of-proportion PH have
somewhat disease-speciﬁc vasculopathy and respond differently to
PAH-speciﬁc drugs as compared with typical group 3 PH patients.
Indeed, a few case reports have shown amelioration of pulmonary
hemodynamics by PAH-speciﬁc vasodilators,9,10 suggesting a prom-
ising role of PAH-speciﬁc agents in this subset.þ81 11 706 7899.
jino).
-NC-ND license.patients with group 3 out-of-proportion PH, who favorably
responded to PAH-speciﬁc vasodilators. We describe the clinical
features of the four cases, and also discuss the potential beneﬁts
and risks of PAH-speciﬁc treatment in this emerging population.
2. Case reports
2.1. Case 1
In July 2010, a 46-year-old man with early-onset chronic
obstructive pulmonary disease (COPD) was referred to our hospital
due to progressive peripheral edema. High resolution computed
tomography (HRCT) exhibited severe emphysematous change
(Fig. 1A) and pulmonary function test (PFT) showed marked
decrease in vital capacity (VC), forced expiratory volume in
1 s divided by forced vital capacity (FEV1/FVC) and diffusing ca-
pacity of the lung for carbon monoxide (DLCO) (Table 1). Echocar-
diography suggested severe PH and right heart catheterization
(RHC) also noted increased MPAP, reduced cardiac index (CI) and
elevated pulmonary vascular resistance (PVR). Cardiac magnetic
resonance (CMR)-derived right ventricular ejection fraction (RVEF)
was reduced. Overall clinical assessment suggested progression of
PH and right heart failure, rather than exacerbation of COPD. Sil-
denaﬁl (20 mg, t.i.d.) and, a week later, beraprost (120 mg, t.i.d.)
Fig. 1. High resolution chest computed tomography ﬁndings in four cases with out-of-proportion group 3 pulmonary hypertension: case 1, a 46-year-old man with early-onset chronic obstructive pulmonary disease (panel A); case 2, a
61-year-old man with rheumatoid arthritis-associated interstitial pneumonia (panel B); case 3, a 69-year-old man with combined pulmonary ﬁbrosis and emphysema (panels C and D); case 4, an 86-year-old man with combined
pulmonary ﬁbrosis and emphysema (panels E and F).
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Table 1
Demographics and responses to the vasodilating treatment of the four patients with group 3 out-of-proportion pulmonary hypertension.
Case 1 Case 2 Case 3 Case 4
Baseline demographics
Age (y)/gender 46/M 61/M 69/M 86/M
Background lung disease COPD CVD-IP CPFE CPFE
Pulmonary function test before vasodilator
treatment
VC (L) (%predicted) 2.31 (63.3) 1.99 (57.9)a 3.26 (102.8) 3.28 (108.8)
FEV1 (L) (%predicted) 0.66 (21.5) 1.68 (63.1)a 1.79 (81.0) 2.26 (117.1)
FEV1/FVC (%) 34.7 85.6a 55.6 71.74
%DLCO 28.4 23.2a 29.0 23.4
%DLCO/VA 38.9 39.3a 39.9 25.6
Clinical variables before and after vasodilator therapy
PAH-speciﬁc vasodilators (dose) Sildenaﬁl (20 mg, t.i.d.)
Beraprost (120 mg, t.i.d.)
Sildenaﬁl (20 mg, t.i.d.) Sildenaﬁl (20 mg, t.i.d.)
Bosentan (62.5 mg, b.i.d.)
Sildenaﬁl
(20 mg, t.i.d.)
Other treatment(s) for systemic/lung disease(s) Tiotropium bromide (18 mg/day) Predonisolone (5 mg/day) Tiotropium bromide (18 mg/day)
Duration between baseline and follow-up
assessment
4 M 3 M 3 M 4 M
WHO Functional capacity IV/ III IV/ IVa IV/ IVb III/ II
PaO2 (Torr) 61/ 45
(Room air)
62/ 115
(O2 5 L/ 5 L)
56/ 115
(O2 9 L/ 12 L)
85/ 81
(O2 3 L/ 3 L)
BNP (pg/ml) 2143/ 59.9 843/ 73 1390/ 32.8 81.3/ 27.8
Mean PAP (mmHg) 41/ 27 52/ 35 47/ 43 32/ 32
CI (L/min/m2) 2.2/ 2.99 2.46/ 2.81 1.66/ 2.24 1.99/ 2.5
PVR (dyn s cm5) 810/ 373 966/ 471 987/ 645 626/ 369
RVEF (%) 9.7/ 15.2 21.8/ 32.1 26.4/ 43.5 34.7/ 47.5
COPD, chronic obstructive pulmonary disease; CVD-IP, collagen vascular disease-interstitial pneumonia; CPFE, combined pulmonary ﬁbrosis and emphysema; PAP, pulmonary
artery pressure; CI, cardiac index; PVR, pulmonary vascular resistance; VC, vital capacity, FEV1, forced expiratory volume in 1 s; RVEF, right ventricular ejection fraction.
a Pulmonary function test was conducted in Feb 2011.
b Resting short breath disappeared at follow-up.
A. Igarashi et al. / Respiratory Medicine Case Reports 9 (2013) 4e76were started in August 2010. He tolerated treatment well without
acute side effects. At follow-up admission 3 months later, his ex-
ertional dyspnea and peripheral edema had improved. RHC showed
signiﬁcant improvement in MPAP, CI and PVR. CMR-derived RVEF
had also improved, whereas arterial blood gas analysis (AGA)
indicated deterioration of pulmonary oxygenation as compared
with that before the vasodilator treatment (Table 1). PFT results did
not change remarkably although tiotropium bromide inhalation
(18 mg/day) was started with PAH-speciﬁc agents 3 months before.
2.2. Case 2
A 61-year-old man diagnosed with rheumatoid arthritis-
associated interstitial pneumonia in 2009 noted progressive dys-
pnea, peripheral edema and hypoxemia in Dec 2011. HRCT revealed
ground glass opacity and honeycomb lung in lower lobes (Fig. 1B).
PFT was not performed due to advanced dyspnea. Echocardiography
suggested PH and RHC showed marked increases in MPAP and PVR,
and CMR-derived RVEF was reduced. These clinical evaluations
suggested right heart failure caused by advanced PH, and sildenaﬁl
(20 mg, t.i.d.) was started in Jan 2012. At the follow-up 4 months
later, he had no resting dyspnea and less peripheral edema, and RHC
showed signiﬁcant reductions in MPAP and PVR. Pulmonary
oxygenation and CMR-derived RVEF had also improved (Table 1).
2.3. Case 3
A 69-year-old man, diagnosed with combined pulmonary
ﬁbrosis and emphysema (CPFE) 2 years previously, was referred to
our hospital due to progressive exertional dyspnea and hypoxia in
October 2010. HRCT revealed emphysematous changes in both
upper lungs (Fig. 1C) and subpleural ground glass opacity in lower
lobes (Fig. 1D). PFT showed preserved VC and mildly reduced FEV1/
FEV whereas DLCO was markedly decreased (Table 1). RHC showed
elevation of MPAP and PVR, and CMR-derived RVEF was reduced.
Sildenaﬁl (20 mg, t.i.d.) and, a week later, bosentan (62.5 mg, b.i.d.)were started. He noted no acute adverse events and exertional
short breath improved slightly. At follow-up assessment 3 months
later, he noted further improvement in his short breath. RHC
showed signiﬁcant reductions in MPAP and PVR, and CMR-derived
RVEF also improved (Table 1).
2.4. Case 4
An 86-year-old man with CPFE (Fig. 1E and F) was admitted due
to progressive exertional dyspnea and hypoxia in Dec 2011. HRCT
and PFT results were consistent with the clinical features of CPFE
(Table 1). RHC showed elevation in MPAP and PVR, whereas tio-
tropium bromide inhalation (18 mg/day) and oxygen treatment for
about a month slightly ameliorated his dyspnea and he was fol-
lowed conservatively. Three months later, however, his exertional
dyspnea remained and RHC showed further elevation in PVR. Sil-
denaﬁl of 20 mg, t.i.d. was started in May 2012. At follow-up
assessment 4 months later, his exertional dyspnea had improved.
RHC showed signiﬁcant reduction in PVR and CMR-derived RVEF
was also improved, but pulmonary oxygenation evaluated did not
show remarkable change (Table 1). In this case, tiotropium bromide
was stopped in July 2012 because of difﬁculty in urination.
This study was conducted in accordance with the amended
Declaration of Helsinki. Independent ethics committees of Hok-
kaido University Graduate School of Medicine approved the pro-
tocol, and written informed consent was obtained from all patients.
3. Discussion
The clinical beneﬁt of PAH-speciﬁc vasodilators in group 3 PH is
controversial.2,11 However, we used vasodilator(s) in the present
four patients for the following reasons. First, all four patients noted
progressive symptoms/signs of PH and right heart failure, with RHC
measurements fulﬁlling the recent criteria of severe group 3 PH.7
Further deterioration of the pulmonary hemodynamics was likely
to critically impair functional capacity of the patients and might be
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was relatively stable in all cases. Indeed, there was no marked
exacerbation of cough or sputum in all four cases. In addition,
sequential PFT (available in cases 1 and 4), and HRCT (available in
cases 1, 3 and 4), and chest X-ray of the four cases did not show any
marked worsening, thus suggesting that parenchymal lung disease
was not the primary cause of the advancing symptoms/signs. Third,
respiratory infection was not indicated by symptoms/signs, blood
tests or imaging studies in the four cases. We thus used PAH-
speciﬁc vasodilators and had favorable outcomes in patient
symptoms/signs and pulmonary hemodynamics.
The degree of hemodynamic improvement was marked in the
four cases. Indeed, MPAP and PVR reduced by 19 15% and 45 8%,
respectively. In addition, CI and CMR-derived RVEF improved by
28 9% and 5110%, respectively. These clinical courses suggested
that PAH-speciﬁc vasodilators improved pulmonary hemody-
namics along with right heart function, which subsequently
appeared to improve patient symptoms such as exertional dyspnea
and peripheral edema.
The underlying pathophysiology of the vascular response to
PAH-speciﬁc treatment was not elucidated in this observational
study. However, it is of clinical interest how the vasodilators could
have improved pulmonary hemodynamics. First, it can be specu-
lated that vascular lesions appeared to have more or less reversible
components. Indeed, PAH-speciﬁc vasodilators would have been
less efﬁcacious if vessel loss or ablation in the damaged lung pa-
renchyma was the primary mechanism of increased PVR. Second, it
can also be assumed that PAH-speciﬁc treatment was efﬁcacious
because the vasculopathy was in its early phase. In fact, pulmonary
vasculopathy would respond poorly to any vasodilator if the
vascular lesion is progressed to heavily ﬁbrotic or hyalinized
phase.12 Finally, the target proteins of vasodilators, particularly of
sildenaﬁl, might have been expressed in the diseased vessels.13
Deterioration of hypoxia is the major concern when using va-
sodilators in hypoxic PH patients with lung disease. Theoretically,
vasodilators can dilate vessels in the poorly ventilated lung ﬁelds,
leading to further deterioration of ventilation/perfusion mismatch
and hypoxia.3 In this regard, PDE-5 inhibitors enhance the nitric
oxide pathway in the well-ventilated lung areas,14 minimizing the
worsening of perfusion/ventilation mismatch when compared
with other PAH-speciﬁc agents. In addition, sildenaﬁl is reported
to better improve arterial oxygenation as compared with other
PDE-5 inhibitors.15 We therefore used sildenaﬁl as the ﬁrst line
agent in all four cases, whereas beraprost (case 1) and bosentan
(case 3) were added for the purpose of further decreases in MPAP.
Importantly, the change in pulmonary oxygenation varied among
the cases. In fact, pulmonary oxygenation improved in case 2,
deteriorated in case 1, and did not change markedly in cases 3 and
4. Further studies are warranted to better predict both favorable
and unfavorable response(s) to PAH-speciﬁc agents in group 3 PH
patients.
Limitations of the present report include a small number of the
subjects and possible selection bias. Regarding the selection bias,
however, we treated four consecutive patients with group 3 out-of-
proportion PH since 2010, in whom suitable interventions to the
progressive vasculopathy were clinically necessary. Another limi-
tation is that medical treatments other than vasodilating therapy
may have affected clinical outcomes. In fact, long-term oxygen
therapy, bronchodilators and/or steroids were used in all four cases,
although these treatments were not modiﬁed during the 3e4
month follow-up period. In case 1, however, tiotropium bromide
was stared simultaneously with vasodilators and might have
affected the changes in dyspnea and PFT results. Furthermore, the
follow-up period was 3e4 months and the long-term impact of
PAH-speciﬁc vasodilators remains to be elucidated.The present report suggests a potential role for PAH-speciﬁc va-
sodilators in the treatment of out-of-proportion group 3 PH patients,
particularly when the vasodilators are started in the early phase of
the disease progression. It should be considered, however, that any
vasodilator therapy potentially worsens hypoxia in such patients. In
addition, a recent phase III trial of ambrisentan, a selective endothelin
receptor-A antagonist, showed higher rates of disease progression or
death in idiopathic pulmonary ﬁbrosis.16 Further studies are neces-
sary with regard to the safety and efﬁcacy of PAH-speciﬁc vasodila-
tors in patients with lung disease and “out-of-proportion” PH.
Funding
None.
Conﬂict of interest
None declared.
References
1. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al.
Guidelines for the diagnosis and treatment of pulmonary hypertension: the
Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the
European Society of Cardiology (ESC) and the European Respiratory Society
(ERS), endorsed by the International Society of Heart and Lung Transplantation
(ISHLT). Eur Heart J 2009;30(20):2493e537. [Epub 2009/08/29].
2. Blanco I, Gimeno E, Munoz PA, Pizarro S, Gistau C, Rodriguez-Roisin R, et al.
Hemodynamic and gas exchange effects of sildenaﬁl in patients with chronic
obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit
Care Med 2010;181(3):270e8. [Epub 2009/10/31].
3. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, et al.
A randomised, controlled trial of bosentan in severe COPD. Eur Respir J
2008;32(3):619e28. [Epub 2008/05/02].
4. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, et al. Severe
pulmonary hypertension and chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2005;172(2):189e94. [Epub 2005/04/16].
5. Stevens D, Sharma K, Szidon P, Rich S, McLaughlin V, Kesten S. Severe pul-
monary hypertension associated with COPD. Ann Transplant 2000;5(3):8e12.
[Epub 2001/01/09].
6. Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al.
Tadalaﬁl therapy for pulmonary arterial hypertension. Circulation
2009;119(22):2894e903. [Epub 2009/05/28].
7. Hoeper MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenﬂo M, et al.
Pulmonary hypertension due to chronic lung disease: updated Recommenda-
tions of the Cologne Consensus Conference 2011. Int J Cardiol 2011;154(Suppl.
1):S45e53. [Epub 2012/01/10].
8. Hurdman J, Condliffe R, Elliot CA, Swift A, Rajaram S, Davies C, et al. Pulmonary
hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2012.
[Epub 2012/09/29].
9. Mercurio V, Carlomagno G, Fazio S. Response to pulmonary vasodilator treat-
ment in a former smoker with combined interstitial lung disease complicated
by pulmonary hypertension: case report and review of the literature. Heart
Lung 2012;41(5):512e7. [Epub 2011/11/08].
10. Shimizu M, Imanishi J, Takano T, Miwa Y. Disproportionate pulmonary hy-
pertension in a patient with early-onset pulmonary emphysema treated with
speciﬁc drugs for pulmonary arterial hypertension. Intern Med 2011;50(20):
2341e6. [Epub 2011/10/18].
11. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N,
et al. Sildenaﬁl for treatment of lung ﬁbrosis and pulmonary hypertension: a
randomised controlled trial. Lancet 2002;360(9337):895e900. [Epub 2002/10/02].
12. Koiwa H, Tsujino I, Ikeda D, Ohira H, Tanino M, Nishimura M. An autopsy case
of pulmonary veno-occlusive disease refractory to imatinib. Eur Respir J
2011;37(4):968e70. [Epub 2011/04/02].
13. Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, et al. Anti-
proliferative effects of phosphodiesterase type 5 inhibition in human pulmonary
artery cells. Am J Respir Crit Care Med 2005;172(1):105e13. [Epub 2005/04/09].
14. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenaﬁl
citrate therapy for pulmonary arterial hypertension. N Engl J Med
2005;353(20):2148e57. [Epub 2005/11/18].
15. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P,
Karadas B, et al. Differences in hemodynamic and oxygenation responses to
three different phosphodiesterase-5 inhibitors in patients with pulmonary
arterial hypertension: a randomized prospective study. J Am Coll Cardiol
2004;44(7):1488e96. [Epub 2004/10/07].
16. Health Canada endorsed important safety information on Volibris. Available from:
http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/medeff/advisories-avis/prof/
2012/volibris_hpc-cps-eng.pdf; 2012.
